Evotec (EVT) Q3 2024 earnings summary

Executive summary

• 2024 marked a pivotal year with significant operational and strategic changes, including a Priority Reset initiative targeting €40 million in annual savings and a comprehensive strategic review to be unveiled in H1 2025.

• Transformation focused on operational excellence, cost optimization, and rebuilding trust for sustainable, profitable growth.

• Strategic collaborations expanded with Sandoz, Novo Nordisk, BMS, Bayer, and Pfizer, supporting growth in cell therapy and biosimilars.

• Grand opening of J.POD biologics facility in Toulouse and strong performance at Just – Evotec Biologics.

• Guidance for full-year 2024 confirmed despite challenging market and overcapacity.

Financial highlights

• Nine-month group revenues reached €575.7 million, down 1% year-over-year; Shared R&D revenue declined 12%, while Just – Evotec Biologics grew 74% to €128.7 million.

• Adjusted group EBITDA for nine months was -€6 million, with Just – Evotec Biologics above breakeven at €0.8 million.

• Gross margin improved from 8.6% in Q2 to 9.8% in Q3, driven by operational leverage in Just – Evotec Biologics.

• Positive free cash flow of €16.7 million in Q3, reversing negative flows in prior quarters, aided by over €100 million in cash proceeds from the BMS partnership.

• Liquidity increased to €303 million in Q3, with further €50 million received post-quarter from R&D tax credit factoring.

Outlook and guidance

• Guidance for 2024 is confirmed: group revenues expected between €790–820 million and adjusted EBITDA of €15–35 million.

• R&D expenditure for 2024 is guided at €50–60 million, focusing on scalable, first-in-class platforms.

• Substantial profit uplift is expected in Q4 from increased revenues and ramp-up of cost savings.

• No guidance for 2025 will be provided until the strategic review concludes in H1 2025.

• Further cost savings and liquidity improvements anticipated in Q4 2024 and into 2025.